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Abstract Chronic inflammation is often associated with
granuloma formation that is a hallmark of many human
diseases. The transcription factor nuclear factor-kappa B
(NF-κB) plays a central role in this process by regulating
the expression of several pro-inflammatory genes. Canna-
binoids (CBs) from Cannabis sativa L. exert a large
number of biological effects including anti-inflammatory
and anti-angiogenic effects. In this study, we investigated
the role of CBs on granuloma formation induced by λ-
carrageenin-soaked sponge implant in rat. Our results show
that local administration of WIN 55,212-2, a CB1/CB2
agonist, given daily or at time of implantation significantly
decreased weight and neo-angiogenesis in granuloma tissue
and inhibited nuclear factor-kappa B (NF-κB)/DNA bind-
ing that was associated with a reduced inducible nitric
oxide synthase (iNOS), cyclooxygenase 2 (COX-2), tumor
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necrosis factor alpha (TNF-α), and vascular endothelial
growth factor (VEGF) messenger RNA (mRNA) and
protein expression. Also, arachidonyl-2-chloroethylamide
(ACEA), a CB1 selective agonist, and JWH-015, a CB2
selective agonist, exhibited the same effects that were
reversed by SR141716-A and SR144528, respectively, CB1
and CB2 selective antagonists. These results indicate that
CBs given locally may represent a potential therapeutic tool
in controlling chronic inflammation avoiding psychotropic
effects.
Keywords Cannabinoids . Chronic inflammation .
Angiogenesis . Nuclear factor-kappa B
Introduction
Chronic inflammation, due to a variety of etiological
agents, represents one of the most diffuse pathology. A
specific hallmark of the inflammatory process is repre-
sented by granulomatous tissue formation that is well-
characterised histologically by the presence of infiltrating
macrophages, epithelial and giant cells, and activated mast
cells (MC) surrounded by a lymphocyte mantle and
proliferating fibroblasts [1]. Angiogenesis is observed
during granulomatous inflammation. It allows the mainte-
nance of tissue perfusion and cellular traffic supporting
chronicity [2–4]. Chronic granuloma formation and angio-
genesis are characterized by the prolonged release of a
wide range of pro-inflammatory and pro-oxidant mediators
[5] from phagocytic cells [6], endothelial cells [7], and mast
cells [8], concomitant with a diminished production of anti-
inflammatory and antioxidant mediators [9]. It has been
shown that the transcription factor NF-κB plays a central
role in most physio-pathological processes, including
granuloma formation [10]. NF-κB up regulates the
expression of several genes involved in chronic inflam-
mation and angiogenesis, including tumor necrosis factor
alpha (TNF-α) and vascular endothelial growth factor
(VEGF), adhesion molecules, chemokines, growth factors,
and inducible enzymes as cyclooxygenase 2 (COX-2) and
nitric oxide syntase-2 (iNOS) [11–13]. These inflammatory
mediators are, in turn, able to regulate NF-κB activation
[14]. Cannabinoids (CBs), the active components of
Cannabis sativa L. (marijuana) and their derivatives, exert
a wide array of effects on the central nervous system (CNS)
as well as on peripheral sites such as the immune,
cardiovascular, digestive, reproductive, and ocular systems
[15]. Most CB effects are mediated by the activation of
specific G-protein-coupled receptors that normally bind to a
family of endogenous ligands: the endocannabinoids [16].
Two types of CB receptors have been identified: the CB1
receptor, mostly expressed in the brain and responsible for
CB psychoactivity [17], and the CB2 receptor, mostly
present in the immune system and not involved in CB
psychoactivity [18]. However, the expression of CB1 and
CB2 receptors on the cells from the immune system has
been extensively documented [19]. Previous studies dem-
onstrated that CBs, such as Δ9THC and a synthetic
analogue, CP55,940 [20], modulate immune response in
vivo and in vitro. In fact, they inhibit proliferative
responses of T lymphocytes [21], cytotoxic T cell activity
[22], macrophage function, antigen presentation [23], and
NO production by macrophages [24]. Furthermore, CBs
have been proposed as anti-inflammatory agents in several
models of acute inflammation, as carrageenin edema [25],
and chronic immune inflammation, as arthritis [26]. CBs
also inhibit tumor angiogenesis in vivo by two mecha-
nisms: a direct inhibition of vascular endothelial cell
migration and suppression of the release of pro-angiogenic
factors, VEGF and MMP [27]. In the light of these
observations, we studied the effects of some CB agonists
in λ-carrageenin-induced granuloma, a model of non-
immune chronic inflammation. Specifically, WIN 55,212-2,
a non-selective synthetic CB1/CB2 agonist, arachidonyl-2-
chloroethylamide (ACEA) and JWH-015, CB1 and CB2
selective agonists, and SR141716-A and SR144528 selec-
tive antagonists were used.
Materials and methods
Sponge implantation
MaleWistar rats (Harlan, Italy) weighing 200–220 g were used
in all experiments. The animals were provided with food and
water ad libitum. The light cycle was automatically controlled
(on, 0700 hours; off, 1900 hours), and the room temperature
was thermostatically regulated to 22±1°C with 60±5%
humidity. Before the experiments, the animals were housed
in these conditions for 3–4 days to become acclimatized.
Sponges were implanted as previously described by Russo et
al. [8]. Briefly, two polyether sponges (0.5×1.5×2.0 cm)
weighing 0.035±0.002 g were implanted subcutaneously on
the back of rats (n=12–18 for each group) under general
anesthesia. Sponges and surgery tools were sterilized by
autoclaving for 20 min at 120°C. λ-Carrageenin (1% w/v;
Sigma) was dissolved in pyrogen-free saline (0.5 ml/sponge),
in the presence or absence of CB agonists and/or antagonists,
and injected into each sponge; saline (0.5 ml/sponge) was
used as control. Ninety-six hours after sponge implant, the
rats were sacrificed in an atmosphere of CO2. The granulo-
matous tissue around the sponge was dissected by using a
surgical blade, weighted, quickly frozen in liquid nitrogen,
and stored at −80°C. Animal care, as well as all experiments,
was in accordance with the European Community Council
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directive 86/609/EEC, and efforts were made to minimize
animal suffering and to reduce the number of animals used.
Treatments
The non-selective CB agonist WIN 55,212-2 (CB1/CB2;
Tocris) was given intraperitoneally daily (5 mg/kg) or
locally (0.01–0.1–1 mg/ml), daily at time 0, i.e., only once
after sponge implantation, or, in other experiments, 3 and
4 days after λ-carrageenin 1% administration, in a volume
of 100 μl/sponge. For each experiment, we used three
animals/treatment: ACEA (0.1 mg/ml), a CB1 full agonist,
and JWH-015 (0.1 mg/ml), a CB2 full agonist, were given
only once at time 0. SR141716A (0.1 mg/ml) and
SR144528 (0.1 mg/ml), a CB1 and a CB2 full antagonist,
respectively, were co-somministrated with WIN 55,212-2
(0.1 mg/ml) only once at time 0. WIN 55,212-3, the
inactive enantiomer of WIN 55,212-2, was used as control.
All CB agonists (Tocris) and antagonists (Sanofi) were
dissolved in ethanol. The highest concentration of ethanol
in the sponges was 10%; therefore, the vehicle alone was
administered to animals to verify if it may interfere with
granuloma formation.
Evaluation of angiogenesis
Angiogenesis was evaluated by both histological inves-
tigations and hemoglobin content measurement. The gran-
ulomatous tissue, i.e., the new formation tissue
encapsulating the sponge, was collected and measured with
a balance weighing a minimum of 0.02 to a maximum of
300 g (KERN EG300-EM), always by the same person who
was blinded for the treatments. In some experiments, the
granulomatous tissue was fixed in formol–methanol (9:1,
v/v) solution at 4°C for 24 h. After dehydration in an
ethanol series and infiltration with xylol, paraffin wax
sections were cut at 4–6 μm and stained with hematoxylin
and eosin. Vessels counting was performed on five
randomly selected sections using a 100× objective lens.
In some experiment, the granulomatous tissue was
homogenized on ice with the Polytron PT300 tissue
homogenizer in 1× PBS (4 ml each gram of wet weight)
Fig. 1 Effects of WIN 55,212-2
on λ-carrageenin-induced gran-
ulomatous tissue formation.
a WIN 55,212-2 was adminis-
trated daily intra-peritoneally
(i.p.; 5 mg/kg) or locally (site;
0.1 mg/ml). b and c WIN
55,212-2 (0.1 mg/ml) was
injected locally in daily admin-
istration (daily), single adminis-
tration at time of implantation
(t=0), or single administration 3
and 4 days after implantation
(t=3–4). Granulomatous tissue
formation was evaluated 96 h
after implantation as wet weight
of tissue around the sponge in a
and b and as hemoglobin con-
tent in c. Data are expressed as
mean±SEM of n=3 separate
experiments; ***p<0.001 vs
saline, °°°p<0.001 vs λ-
carrageenin alone. d A repre-
sentative histological analysis
and relative counting of vessels
in granulomatous tissue from
saline-, λ-carrageenin-, and
λ-carrageenin+WIN-55,212-2-
treated sponges at t=0. Fields
are representative of three
separate experiments. Original
magnification, 100×
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as previously described [28]. Briefly, after centrifugation at
2,500×g for 20 min at 4°C, the supernatant was further
centrifuged at 5,000×g for 30 min, and hemoglobin
concentration in the supernatant was determined spectro-
photometrically at 450 nm by using the hemoglobin assay
kit (Sigma Diagnostic). The hemoglobin content was
expressed as milligram hemoglobin per gram of wet weight.
Myeloperoxidase activity
Myeloperoxidase (MPO), a marker of polymorphonuclear
(PMN) leukocyte accumulation, was determined as previ-
ously described by Mullane et al. [29]. Briefly, 96 h after
sponge implantation, the granulomatous tissue was re-
moved and weighed. The tissue was homogenized in a
solution containing 0.5% hexa-decyl-trimethyl-ammonium
bromide dissolved in 10 mM potassium phosphate buffer
(pH 7) and centrifuged for 30 min at 20,000×g at 37°C. An
aliquot of the supernatant was then allowed to react with a
solution of tetra-methyl-benzidine (1.6 mM) and 0.1 mM
H2O2. The rate of change in absorbance was measured
spectrophotometrically at 650 nm. MPO activity was
determined as the amount of enzyme degrading 1 mmol
of peroxide per min at 37°C and was expressed in milliunits
per 100 mg of wet tissue weight.
Preparation of cytosolic and nuclear extracts
For homogenization, tissue was suspended in ice-cold
hypotonic lysis buffer [20 mM 4-2-hydroxyethyl-1-
piperazineethanesulfonic acid (HEPES), 100 mM MgCl2,
0.4 M NaCl, 0.5 mM phenylmethylsulphonylfluoride,
15 μg/ml soybean trypsin inhibitor, 3 μg/ml pepstatin A,
2 μg/ml leupeptin, 40 μM benzamidine, 1 mM dithio-
threitol, 1% Nonidet P40, 20% glicerol) in a ratio of 0.4 ml
per 100 μg of tissue and homogenized at the highest setting
for 2–5 min in Polytron PT300 tissue homogenizer. Protein
concentration was determined using the BioRad protein
assay kit. After homogenization the cytoplasmic fraction
was then obtained by centrifugation for 1 min at 13,000×g.
The nuclear pellet was resuspended in 60 μl of high salt
extraction buffer [20 mM HEPES at pH 7.9, 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM ethylenediaminetetraacetic
acid (EDTA), 25% v/v glycerol, 0.5 mM phenylmethyl-
sulphonylfluoride, 1.5 μg/ml soybean trypsin inhibitor,
7 μg/ml pepstatin A, 5 μg/ml leupeptin, 0.1 mM benza-
midine, 0.5 mM dithiothreitol (DTT)] and incubated with
shaking at 4°C for 30 min. The nuclear extract was then
centrifuged for 15 min at 13,000×g, and the supernatant
was aliquoted and stored at −80°C. The protein concen-
tration was determined by the BioRad protein assay kit.
Electrophoretic mobility shift assay
Double-stranded oligonucleotide containing the NF-κB
recognition sequence (5′-CAACGGCAGGGGAACTCCC
TCTCCTT-3′) was end-labeled with 32P-γ-ATP. Nuclear
extracts (5 μg) were incubated for 15 min with radiolabeled
oligonucleotides (2.5–5.0×104 cpm) in 20 ml reaction buffer
containing 2 mg poly dI–dC, 10 mM Tris–HCl (pH 7.5),
100 mM NaCl, 1 mM EDTA, 1 mM DL–dithiothreitol,
1 mg/ml bovine serum albumin, and 10% (v/v) glycerol.
The specificity of the NF-κB/DNA binding was determined
by competition reaction in which a 50-fold molar excess of
unlabeled wild-type, mutant, or Sp-1 oligonucleotide was
added to the binding reaction 15 min before the radiolabeled
probe. In supershift assay, antibodies reactive to p50 or p65
proteins were added to the reaction mixture 15 min before the
Fig. 2 Effects of WIN 55,212-2 on λ-carrageenin-induced NF-κB
activation in granuloma tissue. The representative electrophoretic
mobility shift assay (a) and the densitometric analysis of the
corresponding bands (optical density; b) showing NF-κB/DNA-
binding activity in nuclear extracts from granulomatous tissue at
96 h. Data in a are representative of three separate experiments. The
results in b are expressed as mean±SEM of n=3 separate experi-
ments; ***p<0.001 vs saline and °°°p<0.001 vs λ-carrageenin alone.
c) Characterization of NF-κB/DNA complex was performed in tissue
from λ-carrageenin-soaked sponges. In competition reaction, nuclear
extracts were incubated with radiolabeled NF-κB probe in the absence
or presence of identical but unlabeled oligonucleotide (W.T., 50×),
mutated non-functional NF-κB probe (Mut., 50×), or unlabeled
oligonucleotide containing the consensus sequence for Sp-1 (Sp-1,
50×). In supershift experiments, nuclear extracts were incubated with
antibodies against p50, p65, and p50+p65 15 min before incubation
with radiolabeled NF-κB probe. Data are from a single experiment
and are representative of three separate experiments
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addition of the radiolabeled NF-κB probe. Nuclear protein–
oligonucleotide complexes were resolved by electrophoresis
on a 6% non-denaturing polyacrylamide gel in 1× Tris–
borate–EDTA buffer at 150 V for 2 h at 4°C. The gel was
dried and autoradiographed with an intensifying screen at
−80°C for 20 h. Subsequently, the relative bands were
quantified by densitometric scanning of the X-ray films with
GS-700 imaging densitometer (BioRad) and a computer
programme (Molecular Analyst, IBM).
Western blot analysis
The immunoblotting analysis of COX-2, iNOS, TNF-α,
VEGF, p50, p65, histone-1, andβ-actin proteins was performed
on total protein fractions of granulomatous tissue homogenates.
Total proteins were mixed with gel loading buffer (50 mMTris/
10% SDS/10% glycerol 2-mercaptoethanol/2 mg bromophenol
for ml) in a ratio of 1:1 and boiled for 3 min. Equivalent
amounts (50 μg) of each sample were electrophoresed through
a 8–12% discontinuous polyacrilamide minigel. Proteins were
transferred onto nitrocellulose membrane, according to the
manufacturer’s instructions (BioRad). The membranes were
saturated by incubation at 4°C overnight with 10% non-fat dry
milk in 1× PBS and then incubated with the appropriate
antiserum: anti-mouse VEGF antiserum (1:200 v/v, Neo-
Marker), anti-mouse TNF-α (1:250 v/v, NeoMarker), anti-
mouse iNOS (1:2,000 v/v, BD Bioscence), anti-rabbit COX-2
(1:250 v/v, BDBioscence), anti-mouse p50 and anti-mouse p65
(1:1,000 v/v, Santa Cruz), anti-rabbit histone-1 (1:1,000 v/v,
Santa Cruz), and anti-mouse β-actin (1:1,000 v/v, Santa Cruz)
for 2 h at room temperature. Themembranes were washed three
times with 1%Triton X-100 in 1× PBS and then incubated with
anti-mouse or anti-rabbit immunoglobulins coupled to perox-
idase (Dako; 1:2,000 v/v). The immune complexes were
revealed by using enhanced chemiluminescence detection
reagents (Amersham) according to the manufacturer’s instruc-
tions and exposed to Kodak X-Omat film. The protein bands on
X-ray film were scanned and analyzed by densitometric
analysis with a GS-700 imaging densitometer.
mRNA analysis
The iNOS, COX-2, TNF-α, and VEGF mRNA level in
granulomatous tissue was determined by using the semi-
quantitative reverse transcriptase polymerase chain reaction
(RT-PCR) method. Total RNA was extracted from tissue
samples by the use of an ultrapure TRIzol reagent
(GibcoBRL) as directed by the manufacturer. RNA (5 μg)
was then reverse-transcribed in 20 μl with 200 U of
superscript II RNase H-reverse transcriptase (Invitrogen) in
the presence of random hexamers (5 μM), 20 U of RNasin
(Promega), dNTPs (10 mM), for 1 h at 42°C. PCR was
performed on 2 μl of the reverse transcription (RT) reaction
mixture in a final volume of 50 μl with 2.5 U of Taq
polymerase (Roche) and 5 μM of the appropriate primers as
follows: iNOS, 5′-GTGTTCCACCAGGAGATGTTG-3′
(forward primer) and 5′-CTCCTGCCCACTGAGTT
CGTC-3′ (reverse primer); COX-2, 5′-GCCACCTCTG
CGATGCTCTT-3′ (forward primer) and 5′-GTGTT
TGGGGTGGGCTTCAG-3′ (reverse primer); TNF-α, 5′-
CAAGGAGGAGAAGTTCCCAA-3′ (forward primer) and
5′-CGGACTCCGTGATGTCTAAG-3′ (reverse primer);
VEGF, 5′-CGCGAATTCCATGAACTTTCTGCTCTCT-3′
(forward primer) and 5′-TGAGAATTCTAGTTCCCGA
AACCCTGA-3′ (reverse primer); and β-actin, 5′-GGCAC
CACACCTTCTACA-3′ (forward primer) and 5′-CAGG
AGGAGCAATGATCT-3′ (reverse primer). To obtain linear
amplification curves, the complementary DNA (cDNA) mix-
tures were subjected to 10, 15, and 20 cycles for the control β-
actin and 20, 25, and 30 cycles for all other genes under the
Fig. 3 Effects of WIN 55,212-2 on λ-carrageenin-induced NF-κB
subunits nuclear translocation. The representative Western blot (a) and
relative densitometric analysis (b) show p50 and p65 nuclear level in
granulomatous tissue at 96 h. Histone-1 expression is shown as
control. Data in a are from a single experiment and are representative
of three separate experiments. The results in b are expressed as mean±
SEM of three separate experiments; ***p<0.001 vs saline, °°°p<
0.001 vs λ-carrageenin alone
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following conditions: denaturating at 95°C for 1 min, annealing
at 52 or 56°C for 1 min for COX-2 and iNOS or TNFα and
VEGF, respectively, and extension at 72°C for 1 min. The final
extension step was performed at 72°C for 10 min. Fifteen
microliters of aliquots of PCR products were electrophoretically
fractionated through 1% agarose gel containing the fluorescent
Vistra green dye (Amersham Pharmacia Biotech) [30]. The
labeling intensity of the PCR product, which is linear to the
amount of DNA, was quantified using the Molecular Imager
FX and Quantity One software (BioRad).
Statistical
The results were expressed as the mean±SEM of n animals,
where each value is the average of responses in duplicate sites.
Statistical comparisons were made by one-way analysis of
variance (ANOVA) followed by Bonferroni’s test for multiple
comparisons. P<0.05 was considered to be significant.
Results
Effects of systemic and local administration of WIN
55,212-2 on λ-carrageenin-induced granuloma formation
The implant of λ-carrageenin (1%)-soaked sponges on the
back of rats caused, at 96 h, a significant increase of
granuloma formation, evaluated as the wet weight of tissue
around the sponge and compared to implants of saline-
soaked sponges (1.39±0.14 g vs 0.38±0.03 g; n=24–36
sponges from 12–18 rats). The local daily administration of
WIN 55,212-2 (0.1 mg/ml), a non-selective CB1/CB2
agonist, resulted in a significant reduction of granuloma
formation (by 57.5%; p<0.001; n=24 sponges from 12
rats), while the intraperitoneal administration resulted
ineffective (5 mg/ml; Fig. 1a). WIN 55,212-3 (0.1 mg/ml),
the inactive enantiomer of WIN 55,212-2, did not reduce
granuloma formation (data not shown) when given at time 0.
In subsequent experiments, CB agonists were given locally.
The ethanol vehicle did not affect the granuloma formation.
Time-dependent effects of locally injected WIN 55,212-2
on λ-carrageenin-induced granuloma formation
Figure 1b shows the results of the time-course experiments
performed to analyze the effects of WIN 55,212-2 given
locally according to the following schedule: (1) daily
administration, (2) single administration at the time of
implantation (t=0), or (3) administration 3 and 4 days after
implantation (t=3–4). WIN 55,212-2 (0.1 mg/ml) strongly
reduced granuloma formation when given daily (42.5%
inhibition; p<0.001; n=24 sponges from 12 rats) or at time
0 (41.7 % inhibition; p<0.001; n=24 sponges from 12
rats), whereas it was ineffective when administered 3 and
4 days after sponge implantation. Moreover, WIN 55,212-2
(0.01, 0.1, 1 mg/ml) given locally and at time 0 caused a
dose–related inhibition of granuloma formation (0.95±
0.09 g, 0.77±0.02 g, 0.39±0.04 g; n=12–16 sponges from
6–8 rats), compared to λ-carrageenin-soaked sponges. New
micro-vessel formation was valuated by hemoglobin con-
tent and histological analysis. WIN 55,212-2 (0.1 mg/ml)
strongly reduced hemoglobin content in granulomatous
tissue when given daily (55.6% inhibition, p<0.001, n=24
sponges from 12 rats) or at time 0 (47.9% inhibition, p<
Fig. 4 Effects of WIN 55,212-2 on λ-carrageenin-induced COX-2,
iNOS, TNF-α, and VEGF mRNA expression in granulomatous tissue
at 96 h. a Representative Vistra green-stained agarose gel of RT-PCR
products corresponding to COX-2, iNOS, TNF-α, and VEGF mRNA
in granulomatous tissue from sponges injected with saline, λ-
carrageenin (1%), λ-carrageenin+WIN 55,212-2 (0.1 mg/ml). The
expression of β-actin was used as a control for cDNA amount. PCR
was allowed to proceed for 10, 15, and 20 cycles using β-actin primers
and for 25, 30, and 35 cycles using specific primers for all other genes.
Shown are signals corresponding to amplification cycles within the
linear range (Materials and methods). b Quantitative analysis of the
results of three independent experiments expressed in percent after
normalization to β-actin mRNA levels calibrated to the signal of
animals injected with saline solution (0%). c Quantitative analysis of
the results of three independent experiments expressed in percent after
normalization to β-actin mRNA levels calibrated to the signal of
animals injected with λ-carrageenin. **p<0.01, ***p<0.001 vs saline;
°°p<0.01, °°°p<0.001 vs λ-carrageenin alone
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0.001, n=24 sponges from 12 rats), whereas it was
ineffective when administered 3 and 4 days after sponge
implantation (Fig. 1c). Moreover, the anti-angiogenic effect
of WIN 55,212-2 given locally at time 0 was confirmed by
histological analysis. Vessels formation was evaluated in
paraffined sections from saline, λ-carrageenin, and WIN-
55,212-2-soaked sponges by light microscopy (5.45±0.38,
13.45±0.54, 6.34±0.58 vessels; p<0.001; n=15 sections
from 9 rats; Fig. 1d).
Effects of WIN 55,212-2 on λ-carrageenin-induced NF-κB
activation
The granuloma formation was correlated with NF-κB
activation. To detect NF-κB/DNA-binding activity, nuclear
extracts from granuloma tissue were analyzed by Electro-
phoretic mobility shift assay (EMSA; Fig. 2a,b). A basal
level of NF-κB/DNA-binding activity was detected in
nuclear extracts of granuloma tissue from saline-treated
sponges harvested 96 h after implant. Carrageenin induced
a marked increase of NF-κB activation that was reduced by
local administration of WIN 55,212-2 (0.1 mg/ml, by
54.5%, p<0.001, n=16 sponges from 8 rats) at time 0.
The composition of the NF-κB complex activated by
carrageenin was determined by competition and supershift
experiments (Fig. 2c). The specificity of NF-κB/DNA-
binding complex was demonstrated by the complete
displacement of the NF-κB/DNA binding in the presence
of a 50-fold molar excess of unlabeled NF-κB probe (Wild
type, 50×) in the competition reaction. In contrast, a 50-fold
molar excess of unlabeled mutated NF-κB probe (Mutated,
50×) or Sp-1 oligonucleotide (Sp-1, 50×) had no effect on
this DNA-binding activity. The composition of the NF-κB
complex activated by carrageenin was determined by using
specific antibodies against p50 and p65 subunits of NF-κB
proteins. The addition of either anti-p50 or anti-p65 and
their combination to the binding reaction resulted in a
characteristic retarded band, as well as a marked reduction
Fig. 5 Effects of WIN 55,212-2
on λ-carrageenin-induced NF-κB
regulated gene expression in
granulomatous tissue at 96 h.
Representative Western blot anal-
ysis and relative densitometric
analysis of iNOS (a), COX-2 (b),
TNF-α (c), and VEGF (d). β-actin
expression is shown as control (e).
Data are representative of three
separate experiments. Results are
expressed as mean±SEM of three
experiments. ***p<0.001 vs saline
and °°°p<0.001 vs λ-carrageenin;
***p<0.001 vs saline and
°°°p<0.001 vs λ-carrageenin
alone
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of NF-κB band intensity, suggesting that the NF-κB
complex contained p50 and p65 heterodimers. Moreover,
the presence of p50 and p65 subunits in nuclear fraction
was examined by immunoblotting analysis (Fig. 3). In
carrageenin-treated sponges, p50 and p65 nuclear level was
increased as compared to saline. The administration of WIN
55,212-2 prevented the nuclear translocation of p50 and p65
subunits (by 68.4 and 53.1%, respectively; p<0.001, n=16
sponges from 8 rats).
Effects of WIN 55,212-2 on NF-κB-regulated gene
expression
We investigated the effects of WIN 55,212-2 on the
expression of several NF-κB-regulated pro-inflammatory
mediators. We determined the abundance of iNOS, COX-2,
VEGF, and TNF-α mRNA in the granulomatous tissue
around sponge implants 96 h after treatment with saline
solution, λ-carrageenin, and λ-carrageenin/WIN 55,212-2.
Specifically, we subjected the total RNA to RT reaction and
the resulting cDNA to semi-quantitative PCR-utilizing
specific primers (“Materials and methods”). The obtained
signals were quantified using Phosphor-Imager. We also
amplified the same cDNA preparation with primers for β-
actin mRNA as an internal control. Our results show that
iNOS, COX-2, VEGF, and TNF-α transcripts were signif-
icantly increased in the granulomatous tissue around λ-
carrageenin-soaked sponges, when compared to the tissue
from saline-soaked sponges (n=8–12 sponges from 4–6
rats). The administration of WIN 55,212-2 strongly
inhibited iNOS, COX-2, VEGF, and TNF-α mRNA
expression compared to mRNA levels in tissue from λ-
carrageenin-soaked sponges (Fig. 4). In addition, these
results were confirmed by immunoblotting analysis. WIN
55,212-2 was able to significantly reduce protein amounts
of COX-2, iNOS, TNF-α, and VEGF (by 56.09, 76.8, 62.5,
and 55.6, respectively; p<0.001; n=8–12 sponges from 4–6
rats) induced by λ-carrageenin (Fig. 5). These findings
demonstrate that WIN 55,212-2 is able to down regulate the
expression of NF-κB-regulated pro-inflammatory mediators
in this model of chronic inflammation.
Effects of CB receptor selective agonists and antagonists
on λ-carrageenin-induced granuloma formation
ACEA (0.1 mg/ml), a CB1 selective agonist, and JWH-015
(0.1 mg/ml), a CB2 selective agonist, when given locally at
the time of sponge implantation, were able to reduce
granuloma formation (by 39.5%, p<0.05, n=16–18
sponges from 8–9 rats for ACEA; by 50.7%, p<0.01, n=
16–18 sponges from 8–9 rats for JWH-015) at the same
extent as WIN 55,212-2. Moreover, the effect of WIN
55,212-2 was reverted by the co-administration of SR141716-
A (0.1 mg/ml), a CB1 selective antagonist, and SR144528
(0.1 mg/ml), a CB2 selective antagonist (Fig. 6a).
Effects of CB receptor agonists and antagonists
on λ-carrageenin-induced leucocytes infiltration
Granulomatous tissue induced by λ-carrageenin was char-
acterized by an increase in MPO activity, an indicator of
PMN, compared to saline injected sponge. Local treatment at
time 0 with WIN 55,212-2 (0.1 mg/ml), ACEA (0.1 mg/ml),
and JWH-015 (0.1 mg/ml) significantly reduced the degree
of PMN infiltration, determined as an increase in MPO
activity (by 39.7, 42.2, and 45.1%, respectively; p<0.001,
n=16–18 sponges from 8–9 rats). Moreover, the effect of
WIN 55,212-2 was reverted by the co-administration of
Fig. 6 Effects of ACEA (0.1 mg/ml), JWH-015 (0.1 mg/ml),
SR141716-A (0.1 mg/ml), and SR144528 (0.1 mg/ml) in comparison
to WIN 55,212-2 (0.1 mg/ml) on λ-carrageenin-induced granuloma
formation. All cannabinoid agonists and antagonists were injected
locally at the time of implantation. Granulomatous tissue formation
was evaluated 96 h after implantation as wet weight of tissue around
the sponge in A and as mieloperoxidase activity in B. Each bar shows
the mean±SEM of three separate experiments. n.s. The difference
among the different treatments is not significant. ***p<0.001 vs
saline; °p<0.05, °°p<0.01, °°°p<0.001 vs λ-carrageenin alone
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SR141716-A (0.1 mg/ml) and SR144528 (0.1 mg/ml;
Fig. 6b).
Effects of CB receptor selective agonists and antagonists
on λ-carrageenin-induced NF-κB activation
We investigated the effects of ACEA (0.1 mg/ml) and
JWH-015 (0.1 mg/ml) selective agonists as well as
SR141716-A (0.1 mg/ml) and SR144528 (0.1 mg/ml)
antagonists on NF-κB/DNA-binding activity in nuclear
extracts from granuloma tissue by EMSA (Fig. 7a). A
basal level of NF-κB/DNA-binding activity was detected in
nuclear extracts of granuloma tissue from saline-treated
sponges harvested 96 h after implant. λ-Carrageenin
induced a marked increase of NF-κB activation that was
reduced by local administration of ACEA (by 51.8%, p<
0.001, n=16–18 sponges from 8–9 rats) and JWH-015 (by
55.6%, p<0.001, n=16–18 sponges from 8–9 rats), as well
as WIN 55,212-2, whereas SR141716-A and SR144528
reverted this effect. Moreover, the presence of p50 and p65
subunits in nuclear fraction was examined by immunoblot-
ting analysis (Fig. 7b). In λ-carrageenin-treated sponges,
p50 and p65 nuclear levels were increased as compared to
saline. The administration of ACEA and JWH-015 pre-
vented the nuclear translocation of p50 and p65 subunits
(by 66.6 and 69.2%, respectively, for p50; by 48.05% and
59.9% for p65, respectively; p<0.001; n=16–18 sponges
from 8–9 rats) as well as WIN 55,212-2, whereas
SR141716-A and SR144528 reverted this effect. Histone-
1 was used as an internal control (data not shown).
Discussion
We investigated the potential protective role of synthetic
CB agonists on granuloma formation induced by λ-
carrageenin-soaked sponge implant in rat. We show that
daily administration of the non-selective CB1/CB2 receptor
agonist, WIN 55,212-2, resulted in a significant reduction
of granuloma formation when it was given locally, while,
when WIN 55,212-2 was administered systemically, gran-
ulomatous tissue formation was only slightly and not
significantly reduced. Moreover, in time-course experi-
ments, we demonstrated that WIN 55,212-2 significantly
decreased both the weight and hemoglobin content of
granulomatous tissue when given at time 0, at the same
extent as daily administration, but it failed to reduce the
granuloma weight and hemoglobin content when given at
time 3 and 4. These results suggest that WIN 55,212-2 is
more effective in preventing the development of granuloma
than in reducing the chronic process when it is already
switched on. In this paper, we also provide evidence for the
Fig. 7 Effects of cannabinoids agonists and antagonists λ-carrageenin-
induced NF-κB activation in granuloma tissue at 96 h. Representative
electrophoreticmobilityshiftassayandtherelativedensitometricanalysis
(a) shows the NF-κB/DNA-binding activity in nuclear extracts from
granulomatous tissue. Representative Western blot and relative
densitometric analysis (b) shows the nuclear levels of p50 and p65
in granulomatous tissue. All cannabinoid agonists and antagonists
(0.1 mg/ml) were injected locally at the time of implantation. Data
are representative of three separate experiments. Results are expressed
as mean±SEM of n=3 separate experiments. n.s. The difference
among the different treatments is not significant. ***p<0.001 vs
saline, °°°p<0.001 vs λ-carrageenin alone
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local efficacy of WIN 55,212-2, given at time 0, in reducing
leukocyte infiltration and new vessel formation induced by
carrageenin in granulomatous tissue. This may be relevant,
as the systemic administration of CB agonists has, as a
limit, psychotropic effects due to CB1 receptor activation in
the central nervous system. Our data are in agreement with
other studies demonstrating the protective effects of WIN
55,212-2 and of other synthetic CBs, as HU-210, in animal
models of arthritis [26], but enlarge the study also to the
new angiogenesis related to a chronic inflammatory
process.
To investigate the molecular mechanism underlying
WIN 55,212-2 anti-inflammatory/anti-angiogenic effect,
we studied the role of WIN 55,212-2 on NF-κB activation
in the granulomatous tissue. NF-κB regulates, at transcrip-
tional level, the expression of several pro-inflammatory and
pro-angiogenic genes, including those encoding for COX-2,
iNOS, TNF-α, and VEGF. Our data show that WIN
55,212-2, locally injected at time 0, decreased NF-κB
activation, which was correlated to a decrease in COX-2,
iNOS, TNF-α and VEGF mRNA, and protein levels in
granulomatous tissue.
It has been suggested that anandamide is able to inhibit
TNFα-dependent activation of NF-κB by targeting both
IKKβ and, to a lesser extent, IKKα, thus, blocking IκBα
degradation [31]. Moreover, dexanabinol reduces NF-κB
activation by inhibiting phosphorylation and degradation of
IκBα [32], although the mechanism by which CBs target
NF-κB remains unclear. Our results indicate that WIN
55,212-2 is able to prevent the activation of NF-κB, which,
in turn, leads to the inhibition of the expression of mediators
involved in the chronic inflammatory process and angiogen-
esis. We have previously demonstrated that, by using a
decoy oligonucleotide for NF-κB, it was possible to prevent
the formation of granulomatous tissue formation in rat [10];
moreover, we and other groups have shown the inhibition of
NF-κB activation by both natural and synthetic CBs in in
vitro models of inflammation [32, 33].
To discriminate if the anti-inflammatory effect of WIN
55,212-2 was mediated by CB1 or CB2 receptor agonist, we
tested ACEA and JWH-015, a CB1 and a CB2 selective
agonist, respectively, on granuloma formation. In our
experimental conditions, no statistical significant difference
between ACEA, JWH-015, and WIN 55,212-2 was
observed in reducing granulomatous tissue formation,
leukocyte infiltration, and NF-κB activation by preventing
the nuclear translocation of p50 and p65 subunits. All the
effects of WIN 55,212-2 were reverted by SR141716-A and
SR144528, CB1 and CB2 selective antagonists, respective-
ly. Therefore, our results show that the anti-inflammatory
and anti-angiogenic effects of WIN 55,212-2 are mediated
by both CB1 and CB2 receptors, through the inhibition of
NF-κB activation in this chronic model of inflammation,
although the molecular mechanism leading to NF-κB
activation is still unclear. It is known that immune cells
could express both receptors on the membrane surface; for
example, mast cells, the major cell-type involved in the
etiopathogenesis of granuloma formation, express both CB1
and CB2 receptors [34]. Furthermore, CBs could decrease
the release of nitric oxide and other pro-inflammatory
mediators equally through CB1 and CB2 receptor activation
in macrophage cell lines [24]. Moreover, it has been
recently reported that endogenous and exogenous CBs
trigger NF-κB-dependent apoptosis in immune cells
through the activation of both CB1/CB2 receptors [19].
In the light of the above reported data, we suggest that
CB agonists prevents λ-carrageenin-induced granuloma
formation and related angiogenesis through a CB1/CB2
receptor-dependent mechanism inhibiting NF-κB activation
and NF-κB-dependent pathways.
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